Abstract
The effects of media, pH, cations, serum, CO2 or anaerobic atmosphere, inoculum size and time of incubation on the in vitro potency of azithromycin were determined. The potency of azithromycin against all genera was particularly sensitive to changes in pH. The MIC forStaphylococcus aureus strains ranged from 50 µg/ml at pH 6 to ≤ 0.025 µg/ml at pH 8; for erythromycin the MIC change was less (1.6 to 0.05 µg/ml). Incubation for 18 h in 5 % CO2 or an anaerobic atmosphere (10 % CO2, 10 % H2, 80 % N2) lowered the pH by approximately 0.8 units with gram-negative organisms and 0.4 units with gram-positive organisms. This resulted in an MIC eight times greater than the aerobic MIC. In addition, the MIC100 for azithromycin and erythromycin againstBacteroides strains growing in Wilkins-Chalgren broth fell from 3.1 µg/ml in the anaerobic atmosphere to 0.2 and 0.4 µg/ml, respectively, when using the Oxyrase enzyme system to remove oxygen. With the Oxyrase system, the pH of the medium at the MIC remained at 7.2, while it fell to 6.7 in the anaerobic gas mixture. An increase in potency for both agents was also observed with other anaerobic species when using the Oxyrase system. The addition of serum produced an increase in potency of azithromycin and erythromycin that correlated with an increase in pH during incubation, despite the use of buffered media. Adding cations to Mueller-Hinton broth resulted in increased MICs for gram-negative organisms; the highest increases observed were four-fold forEscherichia coli. The activity of control antibiotics was not affected to the same degree as that of azithromycin. Increasing the incubation period from 24 to 48 h did not change the MIC values of azithromycin forStaphylococcus aureus orEscherichia coli; however, the MBC values were lower at 48 h and equalled the MIC values. Inoculum size or manner of preparation had no significant effect on the potency of azithromycin.
Similar content being viewed by others
References
Bright MG, Nagel AA, Bordner J, English AR, Retsema JA, Anderson MR et al.: Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. Journal of Antibiotics 1988, 41: 1029–1047.
Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrobial Agents and Chemotherapy 1987, 31: 1939–1947.
Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA: Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy 1987, 31: 1948–1954.
Jones K, Felmingham D, Ridgway G: In vitro activity of azithromycin (CP-62,993), a novel macrolide, against enteric pathogens. Drugs Under Experimental and Clinical Research 1988, 14: 613–615.
Kitzis MD, Goldstein FW, Miegi M, Acar JA: In vitro activity of azithromycin, against various gram-negative bacilli and anaerobic bacteria. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 15–18.
Neu HC, Chin NX, Saha G, Labthavikul P: Comparative in vitro activity of the new oral macrolide azithromycin. European Journal of Clinical Microbiology and Infectious Disease, 1988, 7: 541–544.
Barry AL, Jones RN, Thornsberry C: In vitro activities of azithromycin (CP-62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin and clindamycin. Antimicrobial Agents and Chemotherapy 1988, 32: 752–754.
Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes P: Comparative in vitro activities of new 14-, 15- and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 1988, 32: 1710–1719.
Holdeman LV, Moore WEC: Anaerobe Laboratory Manual. Virginia Polytechnic Institute and State University, Blacksburg, 1972, p. 124.
Bannatyne RM, Jackowski J: Protein binding of ceftriaxone. Current Therapeutic Research 1986, 40: 987.
National Committee of Clinical Laboratory Standards: Methods for Dilution. Antimicrobial susceptibility tests for bacteria that grow aerobically. V 5, N 22. NCCLS, Villanova, PA, 1985.
Fiese EF, Steffen S: Comparison of the acid stability of azithromycin and erythromycin A. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 39–47.
Hardy DJ, Hanson CW, Hensey DM, Beyer JM, Fernandes PB: Susceptibility ofCampylobacter pylori to macrolides and fluoroquinolones. Journal of Antimicrobial Chemotherapy 1988, 22: 631–636.
Dunkin KT, Jones S, Howard AJ: The in vitro activity of CP-62,993 againstHaemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci. Journal of Antimicrobial Chemotherapy 1988, 21: 405–411.
Hansen SL, Swomley P, Drusano G: Effect of carbon dioxide and pH on susceptibility ofBacteroides fragilis group to erythromycin. Antimicrobial Agents and Chemotherapy 1981, 19: 335–336.
Girard AE, Girard D, Retsema JA: Correlation of the extravascular pharmacokinetics of azithromycin with in vivo efficacy in models of localized infection. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 61–71.
Retsema JA, Girard AE, Girard D, Milisen WB: Relationship of high tissue concentrations of azithromycin in bactericidal activity and efficacy in vivo. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A: 83–89.
Fernandes PB, Bailer R, Swanson R, Hanson CW, McDonald E, Ramer NR, Hardy D, Shipkowitz N, Bower RR, Gade E: In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrobial Agents and Chemotherapy 1986, 30: 865–873.
Jones RN, Barry AL: Unpredictable influence of human serum on antimicrobial activity of erythromycin and three oxime ether macrolides. European Journal of Clinical Microbiology 1987, 61: 81–82.
Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. Journal of Antimicrobial Chemotherapy 1990, 25, Supplement A, 73–82.
Hancock REW, Raffie VJ, Nicas TI: Involvement of the outer membrane in gentamicin and streptomycin uptake and killing ofPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1981, 19: 777–785.
National Committee of Clinical Laboratory Standards: Methods for Dilution. Antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd Edition. Document M7-A2, p. 13. NCCLS, Villanova, PA, 1990.
Foulds G, Chan KH, Johnson JT, Shepard RM, Johnson RB: Concentration of azithromycin in human tonsillar tissue. European Journal of Clinical Microbiology and Infectious Diseases 1991, 10, 853–856.
Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D: Azithromycin concentrations at the sites of pulmonary infection. European Respiratory Journal 1990, 3: 886–890.
Christian GD: Analytical chemistry. John Wiley, New York, 1987, p. 572.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Retsema, J.A., Brennan, L.A. & Girard, A.E. Effects of environmental factors on the in vitro potency of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 10, 834–842 (1991). https://doi.org/10.1007/BF01975836
Issue Date:
DOI: https://doi.org/10.1007/BF01975836